Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle

Journal of Medicinal Chemistry

Volumn 42, Issue 19, 1999, Pages 3789-3799

  Owa, Takashi ^a   Yoshino, Hiroshi ^a   Okauchi, Tatsuo ^a,b   Yoshimatsu, Kentaro ^a   Ozawa, Yoichi ^a   Sugi, Naoko Hata ^a   Nagasu, Takeshi ^a   Koyanagi, Nozomu ^a   Kitoh, Kyosuke ^a  

^a EISAI CO LTD   (Japan)

^b KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDISULAM; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESEARCH; CANCER THERAPY; CELL CYCLE G1 PHASE; COLON CARCINOMA; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; FLOW CYTOMETRY; G1 PHASE; HUMANS; LEUKEMIA P388; MICE; MODELS, CHEMICAL; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0033598320     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902638     Document Type: Article

References (40)

1. Hung, D. T.; Jamison, T. F.; Schreiber, S. L. Understanding and controlling the cell cycle with natural products. Chem. Biol. 1996, 3, 623-639.
2. Yoshino, H.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; Koyanagi, N.; Yoshimatsu, K.; Asada, M.; Watanabe, T.; Nagasu, T.; Tsukahara, K.; Iijima, A.; Kitoh, K. Novel sulfonamides as potential, systemically active antitumor agents. J. Med. Chem. 1992, 35, 2496-2497.
3. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997, 57, 3208-3213.
4. Koyanagi, N.; Nagasu, T.; Fujita, F.; Watanabe, T.; Tsukahara, K.; Funahashi, Y.; Fujita, M.; Taguchi, T.; Yoshino, H.; Kitoh, K. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res. 1994, 54, 1702-1706.
5. (a) Owa, T.; Yoshino, H.; Okauchi, T.; Okabe, T.; Sugi, N.; Ozawa, Y.; Nagasu, T.; Kitoh, K.; Yoshimatsu, K. A novel antitumor agent ER-35744, targeting G1 phase. I. Discovery and structure-activity relationships. Proc. Am. Assoc. Cancer Res. 1996, 37, A2664, 390.
6. (b) Yoshino, H.; Owa, T.; Okauchi, T.; Yoshimatsu, K.; Sugi, N.; Nagasu, T.; Ozawa, Y.; Koyanagi, N.; Kitoh, K. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives. WO 95/07276, 1995.
7. (a) Owa, T.; Yoshino, H.; Okauchi, T.; Sugi, N.; Ozawa, Y.; Nagasu, T.; Fujikawa, Y.; Sawa, Y.; Kitoh, K.; Yoshimatsu, K. A novel antitumor agent ER-35744, targeting G1 phase. I. Drug discovery and overview of preclinical studies. Proc. 9th NCI-EORTC, Ann. Oncol. Suppl. 1996, 7, 399.
8. (b) Ozawa, Y.; Sugi, N.; Watanabe, T.; Nagasu, T.; Owa, T.; Koyanagi, N.; Kitoh, K.; Yoshimatsu, K. A novel antitumor agent ER-35744, targeting G1 phase. II. Antitumor activities in vitro and in vivo. Proc. 9th NCI-EORTC, Ann. Oncol. Suppl. 1996, 7, 140.
9. (c) Watanabe, T.; Sugi, N.; Ozawa, Y.; Owa, T.; Nagasu, T.; Koyanagi, N.; Kitoh, K.; Yoshimatsu, K. A novel antitumor agent ER-35744, targeting G1 phase. III. Studies of mechanism of action. Proc. Am. Assoc. Cancer Res. 1996, 37, A2667, 391.
10. Sherr, C. J. Cancer cell cycles. Science 1996, 274, 1672-1677.
11. (a) Riggs, M. G.; Whittaker, R. G.; Neumann, J. R.; Ingram, V. M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977, 268, 462-464.
12. (b) Newmark, H. L.; Lupton, J. R.; Young, C. W. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. 1994, 78, 1-5.
13. Nakajima, H.; Kim, A. B.; Terano, H.; Yoshida, M.; Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 1998, 241, 126-133.
14. (a) Yoshida, M.; Horinouchi, S.; Beppu, T. Trichostatin and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995, 17, 423-430.
15. (b) Taunton, J.; Hassig, C. A.; Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272, 408-411.
16. Akinaga, S.; Nomura, K.; Gomi, K.; Okada, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother. Pharmacol. 1994, 33, 273-280.
17. At a conference in Tokyo on Dec 3, 1998 (The 3rd International Symposium on Cancer Chemotherapy), Dr. Jean Pierre Armand of the Institute Gustave-Roussy reported clinical trials of CC1-779.
18. Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369, 756-758.
19. Palombella, V. J.; Conner, E. M.; Fuseler, J. W.; Destree, A.; Davis, J. M.; Laroux, F. S.; Wolf, R. E.; Huang, J.; Brand, S.; Elliott, P. J.; Lazarus, D.; McCormack, T.; Parent, L.; Stein, R.; Adams, J.; Grisham, M. B. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15671-15676.
20. Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995, 268, 726-731.
21. Schulte, T. W.; Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42, 273-279.
22. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal structure of an HSP90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
23. Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
24. (a) Sin, N.; Meng, L.; Wang, M. Q. W.; Wen, J. J.; Bornmann, W. G.; Crews, C. M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6099-6103.
25. (b) Griffith, E. C.; Su, Z.; Turk, B. E.; Chen, S.; Chang, Y.-H.; Wu, Z.; Biemann, K.; Liu, J. O. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 1997, 4, 461-471.
26. (c) Liu, S.; Widom, J.; Kemp, C. W.; Crews, C. M.; Clardy, J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998, 282, 1324-1327.
27. Yoshino, H.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; Okada, T.; Koyanagi, N.; Asada, M.; Yoshimatsu, K.; Kitoh, K. E7010, a novel sulfonamide antitumor agent. I. Discovery and structure activity relationships. Proc. Am. Assoc. Cancer Res. 1992, 33, A3082, 516.
28. Singer, H.; Shive, W. Synthesis of 7-nitroindole. J. Org. Chem. 1957, 22, 84-85.
29. Hiremath, S. P.; Siddappa, S. 7-Nitrotryptophan and 7-nitroindole derivatives. Chem. Abstr. 1963, 59, 8855-8857.
30. Sosnovsky, G.; Krogh, J. A.; Umhoefer, S. G. A one-flask conversion of aldehydes to nitriles using hydroxylamine hydrochloride and selenium dioxide. Synthesis 1979, 722-724.
31. Holland, G. F.; Funderburk, W. H.; Finger, K. F. Preparation and anticonvulsant activity of N-substituted benzenedisulfonamides. J. Med. Chem. 1963, 6, 307-312.
32. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
33. Boyd, M. R.; Paull, K. D.; Rubinstein, L. R. Data display and analysis strategies from NCI disease-oriented in vitro antitumour drug screen. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development; Valeriote, F. A., Corbett, T., Baker, L., Eds.; Kluwer Academic Publishers: Amsterdam, 1992; pp 11-34.
34. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the NCI in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-109.
35. Goldin, A.; Venditti, J. M.; Macdonald, J. S.; Mugia, F. M.; Henney, J. E.; Devita, V. T., Jr. Current result of screening program at the division of cancer treatment, National Cancer Institute. Eur. J. Cancer 1980, 17, 129-142.
36. Fiefig, H. H.; Schuchhardt, C.; Henss, H.; Fiedler, L.; Lohr, G. W. Comparison of tumor response in nude mice to clinical response in donor patient. J. Surg. Oncol. 1980, 15, 211-219.
37. Winograd, B.; Boven, E.; Lobbezoo, M. W.; Pinedo, H. M. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development. In Vivo (Athens) 1987, 1, 1-13.
38. Mattern, J.; Bak, M.; Hahn, E. W.; Volm, M. Human tumor xenografts as model for drug testing. Cancer Metast. Rev. 1988, 7, 263-284.
39. Raymond, E.; Fumoleau, P.; Roche, H.; Shellens, H. H. M.; Ravic, M.; Dittrich, C.; Punt, C. J. A.; Droz, J. P.; Armand, J.-P.; Calvert, A. H.; Wanders, J.; Hanauske, A.-R. Pharmacokinetic study of E7070, a novel sulphonamide, combining data from four phase I trials. Proc. Am. Assoc. Cancer Res. 1980, 40, A2545, 384.
40. Sprague, J. M.; Johnson, T. B. The preparation of alkyl sulfonyl chlorides from isothioureas. II. J. Am. Chem. Soc. 1937, 59, 1837-1840.